TASL and bladder transitional cell carcinoma: Analysis of clinical data revealed that TASL expression was positively correlated with longer OS or progress-free survival (PFS) in the immunotherapy-treated BLCA-GSE19423 (P = 0.006), RCC-GSE67501 (P = 0.007), SKCM-GSE91061-all (P < 0.001), SKCM-GSE91061-prog (P < 0.001) cohorts (Fig. 4D).